Markets
Will the AI-discovered natural molecule receive FDA approval by July 2027?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the AI-discovered natural molecule identified by Stanford scientists as having Ozempic-like effects without typical side effects receives FDA approval by July 31, 2027. The market resolves to No if approval has not been granted by this date.
Rules
- Market closes at 7/31/2027.
- Logic weighted resolution applies.
The current odds seem a bit high for FDA approval by July 2027, considering the typical review timelines we’ve seen in recent cases. For instance, vaccines and therapeutics often take three to five years, even with expedited processes. While this AI-discovered molecule might have shown promise in initial studies, there is still extensive testing required to ensure safety and efficacy. It’s worth asking why others are so confident. Has there been new data released that I’m not aware of? I’m skeptical of hitting that deadline unless we really see something groundbreaking soon.
Rationale:The comment provides a well-reasoned analysis of the FDA approval timeline, referencing typical review durations for vaccines and therapeutics, which supports its factual accuracy. It avoids logical fallacies and remains highly relevant to the market question. While it does express skepticism, it balances this with logical reasoning, leading to a slightly lower score in the logic/emotion category. The weights reflect the importance of factual accuracy and logical coherence in this context.
The consensus price for FDA approval by July 2027 feels overpriced. Given the historical rate of novel natural molecules getting through the FDA process, which hovers around 10 percent, the current odds don’t align with the data. Sure, this one has AI backing, but FDA reviews take time, and any safety concerns could drag it out much longer. Just look at past approvals; many promising discoveries got stalled. I see a better entry point once the hype settles down.
Rationale:The comment provides a well-reasoned analysis based on historical data regarding FDA approval rates, which supports its claims about the likelihood of approval. It avoids logical fallacies and directly addresses the market question, making it highly relevant. The emotional appeal is present but balanced with logical reasoning, justifying a slightly lower score in that category. The weights reflect the importance of factual accuracy and logical soundness in this context.
I find it hard to believe this natural molecule will get FDA approval by July 2027. Sure, AI can uncover new compounds, but the approval process is notoriously slow and complicated. Plus, the FDA is extremely cautious when it comes to anything that could impact public health. The price reflects optimism but I think it is miscalculated; we might be looking at a much longer timeline.
Rationale:The comment presents a reasonable skepticism about the FDA approval timeline, supported by the known complexities of the approval process. It avoids logical fallacies and remains relevant to the market question. The weights reflect a balanced emphasis on factual accuracy and logical reasoning, given the comment's focus on the approval process and its implications for the market.
The market is pricing in a 65% chance of FDA approval, but based on previous approvals for similar AI-discovered compounds, I'd estimate closer to 45% given the regulatory complexities. There is always a risk of unexpected roadblocks in clinical trials. Have there been any recent updates on the trial results that could sway this?
Rationale:The comment provides a reasonable estimate of FDA approval chances based on historical data, which is mostly accurate but lacks specific evidence for the 45% figure. It avoids logical fallacies and is relevant to the market question, discussing regulatory complexities and the potential for roadblocks. The weights reflect a balanced focus on factual accuracy and logical reasoning, given the speculative nature of the approval process.
FDA approvals are tough, especially for new molecules, so I doubt this’ll pass by July 2027 unless the data is super strong.
Rationale:The comment accurately reflects the general challenges associated with FDA approvals for new molecules, which is a verifiable fact. It presents a logical skepticism about the approval timeline, free from major logical fallacies. The relevance to the market question is strong, as it discusses the likelihood of FDA approval by the specified date. The weights reflect a balanced focus on factual accuracy and logical reasoning, with some emotional context regarding skepticism about the approval process.
tbh, i think this is way optimistic. sure, AI found the molecule but getting FDA approval takes time. i'm thinking more like 2028, especially with all the red tape.
Rationale:The comment presents a reasonable skepticism regarding the timeline for FDA approval, which is a valid concern given the complexities of the approval process. While it lacks specific data to support the claim about the timeline extending to 2028, it does not contain logical fallacies and is relevant to the market question. The weights reflect a balance between the need for factual accuracy and the logical reasoning behind the opinion expressed.
I think the market is overestimating this one. FDA approvals are super unpredictable, especially for new tech. This feels like a long shot.
Rationale:The comment accurately reflects the unpredictability of FDA approvals, particularly for new technologies, which is a relevant point. However, it lacks specific evidence or data to support the claim that the market is overestimating the likelihood of approval. The weights reflect a balance between the relevance of the comment and the need for factual support, given the speculative nature of the market. Overall, the comment is logical but could benefit from more substantiation.
The current odds seem way too high given the typical timelines for FDA reviews, especially for something new like this; I'd bet against it.
Rationale:The comment provides a reasonable perspective on the FDA review timelines, which is relevant to the market question. However, it lacks specific data to fully support the claim about the odds being too high, leading to a score of 70 for Fact Check. The comment is mostly free of logical fallacies and directly addresses the market outcome, but it does contain some emotional appeal regarding betting against the approval. The weights reflect the importance of relevance and logical reasoning in this context.
tbh, I think this market is way too optimistic; there's always complications with FDA approvals and this molecule's not even on anyone's radar yet. like, I get the hype around AI, but just because it was discovered by a machine doesn't mean it’s a slam dunk.
Rationale:The comment presents a mostly accurate perspective on the challenges of FDA approvals, though it lacks specific evidence regarding the molecule's current status. It addresses the market question directly, highlighting skepticism about the optimism surrounding AI discoveries. The weights reflect a balance between relevance and the need for logical reasoning, given the comment's speculative nature about the FDA process and the molecule's visibility.
why is the market so optimistic about this? we’ve seen a million compounds fail for every one that actually gets approved, and now we’re suddenly trusting some AI to save the day? sounds kinda sketchy if you ask me.
Rationale:The comment raises valid concerns about the optimism surrounding AI-discovered compounds, referencing the historical failure rate of drug approvals. However, it lacks specific data to support the skepticism about AI's role, leading to a score of 70 for Fact Check. The argument is mostly logical with some emotional appeal, hence the balanced scores in No Fallacies and Logic/Emotion. The weights reflect the importance of relevance and logical consistency in this context.